plakotenin: from the Palauan sponge Plakortis lita; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 21775550 |
| CHEMBL ID | 522470 |
| MeSH ID | M0350505 |
| Synonym |
|---|
| CHEMBL522470 |
| plakotenin |
| (e)-3-[(1r,3r,3ar,4s,5s,7ar)-4-ethyl-1,3,7-trimethyl-5-phenyl-1,2,3,3a,5,7a-hexahydroinden-4-yl]-2-methylprop-2-enoic acid |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID381156 | Antiproliferative activity against rheumatoid synovial fibroblasts assessed as inhibition of PDGF-BB-induced DNA synthesis at 0.1 ug/mL treated 15 mins before PDGF-BB challenge by [3H]thymidine incorporation assay | 1999 | Journal of natural products, Aug, Volume: 62, Issue:8 | Homo- and nor-plakotenin, new carboxylic acids from the Palauan sponge Plakortis lita. |
| AID381155 | Antiproliferative activity against rheumatoid synovial fibroblasts assessed as inhibition of PDGF-BB-induced DNA synthesis at 1 ug/mL treated 15 mins before PDGF-BB challenge by [3H]thymidine incorporation assay | 1999 | Journal of natural products, Aug, Volume: 62, Issue:8 | Homo- and nor-plakotenin, new carboxylic acids from the Palauan sponge Plakortis lita. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||